NCT00365300View on ClinicalTrials.gov

Study Evaluating the Efficacy and Safety of Pantoprazole in Infants With Symptomatic Gastroesophageal Reflux Disease (GERD)

PHASE3CompletedINTERVENTIONAL

Enrollment

129

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

November 30, 2007

Study Completion Date

November 30, 2007

Conditions

Gastroesophageal Reflux

Interventions

DRUG

pantoprazole

DRUG

Placebo

Trial Locations (38)

10595

Valhalla

11219

Brooklyn

14222

Buffalo

18017

Bethlehem

20010

Washington D.C.

23219

Richmond

23507

Norfolk

25701

Huntington

26506

Morgantown

27710

Durham

30912

Augusta

32504

Pensacola

32801

Orlando

33101

Miami

33606

Tampa

36604

Mobile

38103

Memphis

39216

Jackson

40004

Bardstown

40202

Louisville

45229

Cincinnati

48503

Flint

53715

Madison

61603

Peoria

68105

Omaha

72205

Little Rock

73104

Oklahoma City

76508

Temple

84113

Salt Lake City

85016

Phoenix

89109

Las Vegas

92868

Orange

94609

Oakland

02114

Boston

08103

Camden

08330

Mays Landing

07962

Morristown

05401

Burlington

All Listed Sponsors

lead

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

NCT00365300 - Study Evaluating the Efficacy and Safety of Pantoprazole in Infants With Symptomatic Gastroesophageal Reflux Disease (GERD) | Biotech Hunter | Biotech Hunter